- Paulson: U.S. Banking System Fundamentally Sound
- Dow Chemical, Kuwait Petroleum Base Venture In Michigan
- "Dark Knight" Brightens Hollywood With Best Weekend Ever
- Tomato Growers: Damage From Salmonella Scare Devastating
- Fed's Stern: Hike Rates Sooner Rather Than Later
- Bank Stocks: Fear Trumps Fundamentals
- Week's Rally Still Leaves Some on the Sidelines
- Stock Chatter Focuses on Financials, Pharma
- Freddie Mac Takes Step Toward Issuing Stock
- Web Extra: Your Earnings Edge And More
- Surprise Friday – Who Could It Be?
- The Latest Picks That Paid – Friday July 18th
- The Fast Money Misfires – Friday July 18th
- Pops & Drops: Intel, General Motors...
- The Future Of Wall Street
- Don’t Dump Everything Energy
- Can Apple Save Tech
- Kilduff: Iran Diplomacy = Lower Oil Prices?
Options activity is picking up in Johnson & Johnson stock. Why?
"I would be inclined to correlate it to the move higher in hepatitis-C drugmakers earlier this week," Rebecca Darst said on CNBC's "Squawk Box." "You know, there was a positive clinical trial from Intermune [ITMN
Loading...
()
] earlier this week that was spectacularly bullish for the stock, and suddenly, analysts are paying attention to this $4 billion possible US-European market for hepatitis-C, which is the leading cause of liver transplants in the US. And we saw appreciable upside in a number of drug companies that have hepatitis-C drugs in the pipeline, among them Schering-Plough [SGP
Loading...
()
], which has been a very volatile stock over the past week; Vertex [VRTX
Loading...
()
]; again, Intermune; and we saw some muted upside in Johnson & Johnson [JNJ
Loading...
()
]."
Click here to see her full comments with input from Jim Cramer.
Print
Email
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes